Figure 6.

Therapeutic efficacy of the ¹⁷⁷Lu-anti-CD55 antibody in vitro and in vivo. (a) Assays of H460 lung cancer cell viability after treatment with IgG, ¹⁷⁷Lu-IgG, anti-CD55, or ¹⁷⁷Lu-anti-CD55. α-CD55 (μg/ml) indicates the concentration of all the antibodies, IgG, ¹⁷⁷Lu-IgG, α-CD55, and ¹⁷⁷Lu-α-CD55. ¹⁷⁷Lu-α-CD55 (MBq) indicates the corresponding amounts of radioactivity of ¹⁷⁷Lu-α-CD55 for the indicated concentration (n = 3; **P < 0.01; Student’s t test). The results are presented as the mean ± SEM (error bars). (b) Assays of H358 cell viability after treatment with IgG, ¹⁷⁷Lu-IgG, anti-CD55, or ¹⁷⁷Lu-anti-CD55 (n = 3; *P < 0.05; Student’s t test). The results are presented as the mean ± SEM (error bars). (c) Effects of ¹⁷⁷Lu-anti-CD55 on the survival of H460 bearing-early pleural metastatic mice (n = 10 for each group; ***P < 0.001; Log-rank (Mantel-Cox) test). (d) Effects of ¹⁷⁷Lu-anti-CD55 on the survival of pleural metastatic mice (n = 10 for each group; **P < 0.01; Log-rank (Mantel-Cox) test).